

## PHARMANUTRA: SHAREHOLDERS' MEETING OF 23 APRIL 2018

- APPROVES THE SEPARATE FINANCIAL STATEMENTS OF PHARMANUTRA S.P.A. AS AT 31
  DECEMBER 2017 AND TAKES NOTE OF THE CONSOLIDATED FINANCIAL STATEMENTS AS
  AT 31 DECEMBER 2017;
- RESOLVES THE DISTRIBUTION OF A GROSS DIVIDEND OF €0.33 PER SHARE;
- APPOINTS A NEW DIRECTOR FOLLOWING THE INCREASE IN THE SIZE OF THE BOARD OF DIRECTORS TO A TOTAL OF EIGHT MEMBERS.

**Pisa, 23 April 2018** - The Ordinary Shareholders' Meeting of PharmaNutra S.p.A. met today on first call.

The Shareholders' Meeting approved the separate financial statements of PharmaNutra as at 31 December 2017, which report a profit of €4.547.972, and resolved the distribution of a dividend of €0.33 per eligible share. The ex-dividend date will be 7 May 2018, with a record date of 8 May 2018 and a dividend payment date of 9 May 2018.

The Ordinary Shareholders' Meeting of PharmaNutra S.p.A. also took note of the consolidated financial statements of the PharmaNutra Group as at 31 December 2017 prepared in accordance with the IFRS, which reported the following main figures:

- Total revenue from sales of €37.86 million, up +15.30%
- **EBITDA** of €9.5 million, up +26.30%
- Net profit for the period of €6 million, up +56.60%
- Net financial debt of €9.1 million, an improvement of €11 million

The Shareholders' Meeting also resolved the increase in the size of the Board of Directors from seven to eight members and appointed Professor Giuseppe Turchetti as a new independent Director, who will remain in office until the date of the Shareholders' Meeting called for the approval of the financial statements for the year ended 31 December 2019.

Andrea Lacorte, Chairman of PharmaNutra, stated: "We are very satisfied with the results achieved and the full consensus obtained, in addition to the approval expressed by all the Directors and Shareholders present at the Shareholders' Meeting: we are moving quickly towards our 2018 targets, to continue achieving the successes that have always characterised our company".

Roberto Lacorte, Vice Chairman of PharmaNutra, stated: "The results approved today by our Shareholders are a source of pride, as well as satisfaction. The unanimous approval of the 2017 separate financial statements is a sign of the significant understanding of the Company's process of growth and development. I'm also extremely happy and proud about the addition of Professor Giuseppe Turchetti to the Board of Directors, who will enhance the work of the management







board, by bringing significant expertise in specific marketing for the health sector. In addition, his presence on the Board will open the way for significant collaboration opportunities with the Istituto Sant'Anna, where Professor Turchetti is a distinguished lecturer in "business economics and management" and "economics and management of innovation in the health sector".

A copy of the separate financial statements as at 31 December 2017, prepared in accordance with the Italian accounting standards, and a copy of the consolidated financial statements of the PharmaNutra Group, prepared in accordance with the IFRS, are available to the public at the Company's registered office in Pisa, Via delle Lenze 216/b, and on the Company's website at <a href="https://www.pharmanutra.it">www.pharmanutra.it</a>, "Investors/Corporate/Shareholders' Meeting" section.

The minutes of the Shareholders' Meeting and the summary report of the voting will be made available to the public in the manner and within the deadlines established by the applicable regulations.

\*\* \*\*\* \*\*

## For More Information:

## PharmaNutra S.p.A.

Via Delle Lenze, 216/b 56122 Pisa Tel. +39 050 7846500 Fax +39 050 7846524 investorrelation@PharmaNutra.it Nomad & Specialist

CFO SIM S.p.A. Via dell'Annunciata 23/4 20121 Milano Tel. +39 02 303431 ecm@cfosim.com **Press Office** 

Spriano Communication&Partners
Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com



